Guggenheim Maintained a Hold Rating on Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE:JNJ) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (NYSE:JNJ) with a price target of $164.

The cautious rating comes as the company gets close to releasing its Q2 2025 earnings results. The second quarter 2025 earnings call is scheduled for July 16. The company released its Q1 2025 results on April 15, where it grew its sales by around 2% year-over-year to $21.9 billion. Johnson & Johnson (NYSE:JNJ) achieved strong growth of nearly 6% in the US market, which helped to offset a struggling international market where it experienced a slowdown.

The main concern for the company remains from a 200% tariff risk by President Trump on Pharmaceuticals. The firm believes the company needs some initiatives aimed at moving away from the tariff risks to improve investor sentiment around the stock.

Johnson & Johnson (NYSE:JNJ) is a healthcare company that operates through two segments, including Innovative Medicine and MedTech.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.